U.S. drug deaths plunged in 2024. Trump cuts may reverse that, experts warn.
U.S. drug deaths plunged in 2024, according to federal data published Wednesday, offering hope that public health measures are paying off even as the toll remains high.
Though there doesn't seem to be a single variable to attribute to the gains, the drop in overdose deaths comes amid concerns that cuts to federal public health agencies and proposals to cut Medicaid could undercut progress.
An estimated 80,391 people died from drugs in 2024, a decrease of nearly 27 percent from the previous year, according to provisional state data collected by the Centers for Disease Control and Prevention. Deaths from synthetic opioids — chiefly fentanyl, which has fueled the overdose crisis during the past decade — played a role in the majority of drug deaths but tumbled by nearly 28,000 fatalities, the estimates show.
The progress comes after drug deaths, which had been rising for more than a decade, soared to staggering levels during the coronavirus pandemic, surpassing 100,000 each year starting in 2021.
'I would characterize this as a historically significant decrease in overdose deaths,' said Brandon Marshall, a Brown University School of Public Health epidemiologist who studies overdose trends. 'We're really seeing decreases almost across the entire nation at this point.'
The data published Wednesday charts a dramatic decline in deaths during then-President Joe Biden's final year in office. The Trump administration has espoused hard-line rhetoric on fentanyl, declaring traffickers a top national security threat and citing them as a key reason for launching trade battles with China and allies Canada and Mexico.
The administration has also touted large fentanyl seizures and asked Mexico to allow the U.S. military to conduct counternarcotics operations on Mexican soil, a request denied by that country's president.
The CDC, in a statement, noted that Trump during his first administration declared the opioid crisis a public-health emergency in 2017. The declines since 2023 are a 'strong sign that public health interventions are making a difference and having a meaningful impact,' the agency said. 'Despite these overall improvements, overdose remains the leading cause of death for Americans aged 18-44, underscoring the need for ongoing efforts to maintain this progress.'
The White House Office of National Drug Control Policy, in an April statement of policy priorities, emphasized curbing the flow of illicit fentanyl, along with expanding access to treatment and research into cutting-edge technologies to identify and address emerging drug threats.
But public health advocates are raising alarm that the Trump administration is undercutting those goals with plans to gut federal funding that helps states pay for overdose antidotes, addiction treatment and other measures. A survey conducted by the nonprofit research firm Rand published in May suggests that more people may be using illicit opioids than previously estimated, underscoring the need for better monitoring.
In a letter to Congress on Monday, more than 300 academics warned that the Trump administration's proposed cuts to the Substance Abuse and Mental Health Services Administration and CDC could 'undermine the hard-fought progress we have made, especially in overdose prevention.'
Experts also worry Republican plans to slash Medicaid could leave former drug users without access to medication, forcing them to turn to street drugs, said Chad Sabora, a drug policy expert who helped organize the letter. 'It will equal more people dying,' he said.
The opioid crisis began decades ago with highly addictive prescription pain killers flooding states. Users later turned to cheaper street heroin, which was largely replaced by fentanyl manufactured by Mexican organized crime groups with precursor chemicals sourced from China. The synthetic drug can be up to 50 times more potent than heroin.
No single reason explains the sudden drop in deaths, researchers and health officials stress.
The Biden administration credited seizures of fentanyl at the southern border, arrests of high-level Mexican drug traffickers and cooperation from Beijing to crack down on unscrupulous Chinese companies exporting precursor chemicals. The administration also expanded access to addiction treatment medications such as buprenorphine, which wards off opioid withdrawals, and the overdose reversal drug naloxone. It also embraced harm reduction organizations that have saturated communities with free naloxone, fentanyl test strips and sterile needles to users.
Fewer deaths 'don't just happen overnight. And that's why we can credit them to the Biden administration's work,' said Sheila P. Vakharia, deputy director of research and academic engagement for the nonprofit Drug Policy Alliance.
Experts also believe that the illicit drug supply, at least in some regions, may be shifting to include less fentanyl. Other drugs added to fentanyl — such as the tranquilizer xylazine — may prolong the sedating effect and stave off opioid withdrawal so that users consume less fentanyl each day, researchers theorize.
Declines in deaths may also reflect the grim reality that fentanyl has killed so many regular users that there are fewer people at risk of overdose. The trajectory of deaths 'can't keep going up. It has essentially to kind of burn itself out,' said Caleb Banta-Green, an addiction expert and drug researcher at the University of Washington School of Medicine.
During Biden's first three years, the death toll topped 100,000 each year.
Deaths during a 12-month period peaked in June 2023 at a staggering 114,670, making the rapid drop nationally all the more remarkable, said Nabarun Dasgupta, an epidemiologist at the University of North Carolina at Chapel Hill. He stressed that deaths had been falling in certain regions where fentanyl had been entrenched for longer.
'Americans have responded to the overdose crisis with powerful community efforts, from every small town to large city. What we are seeing is the fruit of all that collective labor. These local efforts are the heart of overdose prevention,' Dasgupta said.
The CDC data released on Wednesday is not definitive; final death statistics lag because toxicology testing often takes months to complete.
Deaths involving stimulants such as methamphetamine and cocaine — which users increasingly take alongside fentanyl — also decreased, the statistics show.
Two states, Nevada and South Dakota notched slight increases from the previous year. But nearly all states showed declines in 2024. States such as New Hampshire, West Virginia and Ohio recorded declines of 35 percent or more.
In Washington state, where fentanyl became entrenched years later than on the East Coast, suspected drug deaths dropped by nearly 12 percent, after years of increases, for a total of 3,167.
In King County, home to Seattle, health officials distributed 124,700 naloxone kits in 2024 and opened three vending machines for people to obtain the medication, fentanyl test strips and other supplies. County officials and the University of Washington Department of Emergency Medicine also debuted a hotline for doctors to prescribe buprenorphine through free telehealth sessions at any time of day. The city's mayor in August announced an investment of nearly $3 million in opioid litigation settlement money to increase capacity for inpatient treatment.
But the state health department's top medical officer, Tao Kwan-Gett, urged cautioned. Washington overdose deaths fell through much of 2024 but spiked during the final four months of the year.
'It's too early to say that we're seeing a sustained decrease,' Kwan-Gett said. 'I certainly hope we are, but I think we have to continue being vigilant.'
The encouraging statistics in Washington and nationwide belie the heartbreak of addiction — and death.
Among the victims nationwide in 2024: a 17-month-old Los Angeles boy who ingested fentanyl during a child welfare-monitored visit with his mother; a 15-year-old girl who fatally overdosed on fentanyl at her Georgia high school, nine people who fatally overdosed in Austin, during one day.
In Seattle, former movie set designer Wade Paradise battled an opioid addiction for years after taking prescription pain killers. He was largely estranged from his family, living in squalor and suffering from myriad ailments, according to his daughter, Nathalie Paradise, 24.
She said Wade Paradise had struggled to get addiction treatment because of problems with health insurance. In December, he died at age 68 in his home from a pill made of fentanyl. His death received little attention but for Nathalie's GoFundMe page in which she recalled cherished childhood memories of summer swims in a lake and bargain hunting at thrift stores — and detailed his addiction.
'I didn't want it to be a secret anymore. I felt like the people in his life deserved to know the truth,' she said in an interview. 'I also have a lot of friends who use drugs, and I hoped that by sharing my story, it might encourage them to stop.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
PlushCare Launches Enhanced Online Weight Loss Program to Expand National Access to GLP-1 Prescriptions Through Board-Certified Doctors
Secure Online Access to GLP-1 Weight Loss Medications Like Semaglutide Now Available Nationwide Through PlushCare's Updated Virtual Health Platform San Francisco, June 10, 2025 (GLOBE NEWSWIRE) -- PlushCare, a leading virtual healthcare platform, has announced a significant upgrade to its online Weight Loss Program, enabling greater access to GLP-1-based prescription treatments such as semaglutide through board-certified physicians. This development marks a critical milestone in the company's mission to provide affordable, clinically supervised weight management across the United States. Accessible at the updated platform streamlines the process for eligible adults to consult with licensed physicians, receive lab work if necessary, and access customized treatment plans—all from the comfort of their homes. 'We're committed to making evidence-based weight loss solutions more accessible through modern telehealth,' said a PlushCare spokesperson. 'Our program is designed to connect people with experienced doctors who can evaluate eligibility for medications like GLP-1s and deliver a personalized plan that fits their health goals.' Expanded Features for 2025 The revamped Weight Loss Program now includes: Nationwide Access to medical providers via secure telehealth appointments Eligibility Evaluation for FDA-approved medications, including semaglutide Personalized Plans tailored to each user's metabolic profile Optional Lab Testing with integrated results for precision treatment Transparent Pricing with no insurance required The platform is optimized for mobile and desktop users, offering a seamless experience from appointment scheduling to prescription delivery. Addressing a Growing National Health Concern According to the CDC, over 40% of U.S. adults struggle with obesity, with rising demand for effective clinical support. PlushCare's integrated virtual care model delivers a scalable solution that removes traditional geographic and scheduling barriers. Patients can typically get started in under 15 minutes by completing an intake form and booking a same-day appointment with a licensed doctor. If clinically appropriate, a prescription is sent to their preferred pharmacy. About PlushCare PlushCare is a virtual primary care and mental health platform that connects patients with top U.S. medical professionals through its secure telehealth platform. With a commitment to quality care, convenience, and evidence-based treatment, PlushCare is redefining access to modern healthcare. For more information, visit Media Contact:PlushCare Media RelationsEmail: press@ 345 California Street, Suite 600, San Francisco, CA 94105, United States SOURCE: PlushCare Disclaimer: This release contains forward-looking statements and should not be considered medical advice. All treatments are subject to clinical evaluation and provider discretion. CONTACT: Email: press@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


The Hill
26 minutes ago
- The Hill
Trump administration vs. mRNA vaccines
The Big Story President Trump once heralded the speedy development of an mRNA vaccine, but his new administration is casting doubts and fostering speculation over their use. © AP The Department of Health and Human Services (HHS) in late May canceled $766 million awarded to Moderna through the Biomedical Advanced Research and Development Authority (BARDA) to develop a potential mRNA vaccine for bird flu. This came soon after HHS Secretary Robert F. Kennedy Jr. announced COVID-19 mRNA vaccines would no longer be recommended for children and pregnant women, though the Centers for Disease Control and Prevention (CDC) kept the shot on its schedule of childhood vaccinations. The vaccines marked a breakthrough in medical technology, drastically reducing the timeline for development of targeted vaccines and even showing promise in cancer research. Trump called mRNA the 'gold standard' when he rolled out the first COVID-19 vaccines. In remarks in December 2020, the same month the first COVID-19 vaccines were deployed, Trump praised Operation Warp Speed's ability to develop a SARS-CoV-2 vaccine at a 'breakneck speed,' adding, 'the gold standard vaccine has been done in less than nine months.' According to Joseph Varon, president and chief medical officer of the Independent Medical Alliance, the concerns for mRNA vaccine skeptics are the expedited timeline and the conditions in which the COVID-19 vaccine was approved. 'The biggest concern is that this rushed treatment still remains in use, even under an Emergency Use Authorization in some cases. It needs to be sent back through proper studies and vetting,' Varon told The Hill. In a move that could prevent future mRNA vaccines from receiving approval, Kennedy on Tuesday announced he was removing every member of the independent panel advising the CDC on vaccines. In a Wall Street Journal op-ed, he wrote, 'A clean sweep is needed to re-establish public confidence in vaccine science.' Welcome to The Hill's Health Care newsletter, we're Nathaniel Weixel, Joseph Choi and Alejandra O'Connell-Domenech — every week we follow the latest moves on how Washington impacts your health. Did someone forward you this newsletter? Subscribe here. Essential Reads How policy will be impacting the health care sector this week and beyond: Senators grill NIH director in budget hearing: 4 takeaways National Institutes of Health Director Jay Bhattacharya faced questions from senators during an Appropriations subcommittee hearing Tuesday, as the federal government agency has taken hits to its staffing levels and grant-making ability since under President Trump. Senators focused on the Trump administration's requested 2026 budget, which calls for cutting NIH's funding by $18 billion from 2025 levels. … States sue 23andMe over genetic data sales More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to auction off personal genetic information without their customers' knowledge or consent. 'The Pitt' actor Noah Wyle to make push for health care workers at Capitol Noah Wyle is heading to the pit of political power, with a visit to Capitol Hill to push for funding for programs aimed at improving mental health services for health care workers. 'The Pitt' and former 'ER' star will touch down in Washington on Thursday to lead a panel discussion at the Cannon House Office Building focused on the 'daily mental health, financial, and bureaucratic challenges for … In Other News Branch out with a different read: Collins calls Kennedy's firing of vaccine experts 'excessive' Sen. Susan Collins (R-Maine) on Monday called Health and Human Services Secretary Robert F. Kennedy Jr.'s firing of all 17 experts on the U.S. Centers for Disease Control and Prevention's (CDC) vaccine panel 'excessive,' but she cautioned she needs to learn more about the decision. Kennedy announced the decision in an op-ed for The Wall Street Journal, catching many GOP lawmakers by surprise. 'I did not know that that had happened,' … Around the Nation Local and state headlines on health care: What We're Reading Health news we've flagged from other outlets: What Others are Reading Most read stories on The Hill right now: Judge declines to block Trump's Corporation for Public Broadcasting firings but allows board members to stay Correction: A previous version of this article gave incorrect names of the fired CPB board members. They are Laura Ross, Diane Kaplan and Thomas Rothman. … Read more Newsom asks judge for emergency intervention in Trump troop deployment in LA California Gov. Gavin Newsom (D) asked a federal judge to immediately intervene on Tuesday to limit President Trump's deployment of the National … Read more You're all caught up. See you tomorrow! Thank you for signing up! Subscribe to more newsletters here


Bloomberg
31 minutes ago
- Bloomberg
How RFK Jr.'s CDC Ousters Upend the Future of Vaccines
Robert F. Kennedy Jr., US secretary of health and human services, dismissed all 17 members that make up a key committee advising the US government on vaccine safety and policy, saying that removing the entire panel was the only way to restore public confidence in vaccine science. The move, announced in an opinion piece on June 9, added to the confusion about whether Americans would have access to vaccines for diseases from polio and measles to Covid and the flu. Here's what to know about Kennedy's decision and how it might affect future vaccine development and delivery.